2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Supplemental Data Supplemental Data All Versions of this Article: ASN.2009010123v1 20/11/2359    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by LeBleu, V. Articles by Kalluri, R. PubMed PubMed Citation Articles by LeBleu, V. Articles by Kalluri, R. Related Collections Related Article

Stem Cell Therapies Benefit Alport Syndrome

Valerie LeBleu^*,, Hikaru Sugimoto^*, Thomas M. Mundel^*, Behzad Gerami-Naini^*, Elizabeth Finan^*, Caroline A. Miller, Vincent H. Gattone, II, Lingge Lu^*, Charles F. Shield, III, Judah Folkman^|| and Raghu Kalluri^*,,¶

*Division of Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts;
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts;
Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana;
Department of Surgery, University of Kansas School of Medicine, Wichita, Kansas;
^||Vascular Biology Program, Department of Surgery, Children's Hospital, Boston, Massachusetts; and
^¶Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts

Correspondence: Dr. Raghu Kalluri, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Division of Matrix Biology, 330 Brookline Avenue, Boston, MA 02215. Phone: 617-735-4601; Fax: 617-735-4602; E-mail: rkalluri{at}bidmc.harvard.edu

Received for publication January 30, 2009. Accepted for publication July 8, 2009.

Patients with Alport syndrome progressively lose renal function as a result of defective type IV collagen in their glomerular basement membrane. In mice lacking the 3 chain of type IV collagen (Col4A3 knockout mice), a model for Alport syndrome, transplantation of wild-type bone marrow repairs the renal disease. It is unknown whether cell-based therapies that do not require transplantation have similar potential. Here, infusion of wild-type bone marrow-derived cells into unconditioned, nonirradiated Col4A3 knockout mice during the late stage of disease significantly improved renal histology and function. Furthermore, transfusion of unfractionated wild-type blood into unconditioned, nonirradiated Col4A3 knockout mice improved the renal phenotype and significantly improved survival. Injection of mouse and human embryonic stem cells into Col4A3 knockout mice produced similar results. Regardless of treatment modality, the improvement in the architecture of the glomerular basement membrane is associated with de novo expression of the 3(IV) chain. These data provide further support for testing cell-based therapies for Alport syndrome.

Related Article

Cell Therapy for Alport Syndrome

Christine J. Wong and Ian Rogers
J. Am. Soc. Nephrol. 2009 20: 2279-2281. [Full Text] [PDF]

This article has been cited by other articles:

				C. J. Wong and I. Rogers Cell Therapy for Alport Syndrome J. Am. Soc. Nephrol., November 1, 2009; 20(11): 2279 - 2281. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673